Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

Abstract:

Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atrophy measurements. Methods:For our longitudinal study, we investigated structural cortical networks over 1 year derived from 3T MRI in 203 individuals (92 early RRMS patients with mean disease duration of 12.1 ± 14.5 months and 101 HCs). Brain networks were computed based on cortical thickness inter-regional correlations and fed into graph theoretical analysis. Network connectivity measures (modularity, clustering coefficient, local efficiency, and transitivity) were compared between patients and HCs, and between patients with and without disease activity. Moreover, we calculated longitudinal brain volume changes and cortical atrophy patterns. Results:Our analyses revealed strengthening of local network properties shown by increased modularity, clustering coefficient, local efficiency, and transitivity over time. These network dynamics were not detectable in the cortex of HCs over the same period and occurred independently of patients' disease activity. Most notably, the described network reorganization was evident beyond detectable atrophy as characterized by conventional morphometric methods. Conclusion:In conclusion, our findings provide evidence for gray matter network reorganization subsequent to clinical disease manifestation in patients with early RRMS. An adaptive cortical response with increased local network characteristics favoring network segregation could play a primordial role for maintaining brain function in response to neuroinflammation.

journal_name

Ther Adv Neurol Disord

authors

Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

doi

10.1177/1756286419838673

subject

Has Abstract

pub_date

2019-04-24 00:00:00

pages

1756286419838673

eissn

1756-2856

issn

1756-2864

pii

10.1177_1756286419838673

journal_volume

12

pub_type

杂志文章
  • A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures.

    abstract::Topiramate has been widely utilized worldwide as an effective medication against partial- and generalized-onset seizures. Extended-release topiramate was developed to provide patients with the convenience of once-daily dosing and potentially improved tolerability by reducing serum concentration fluctuation. USL255 is ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285615578406

    authors: Chung SS

    更新日期:2015-05-01 00:00:00

  • Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).

    abstract:Background:Gastrointestinal (GI) events are common adverse events (AEs) associated with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing-remitting multiple sclerosis (RRMS). The objective of the TOLERATE study was to evaluate GI tolerability and GI mitigation via symptomatic therapies in pat...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418768775

    authors: Gold R,Schlegel E,Elias-Hamp B,Albert C,Schmidt S,Tackenberg B,Xiao J,Schaak T,Salmen HC

    更新日期:2018-04-18 00:00:00

  • HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.

    abstract:Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420951087

    authors: Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

    更新日期:2020-10-07 00:00:00

  • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

    abstract:OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285614563056

    authors: Hadden RD,Marreno F

    更新日期:2015-01-01 00:00:00

  • Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies.

    abstract:OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an in...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611415309

    authors: Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

    更新日期:2011-09-01 00:00:00

  • Role of immune responses for extracellular matrix remodeling in the ischemic brain.

    abstract::Neuroinflammation is one of the key components contributing to the devastating outcome of ischemic stroke. Starting with stroke onset, inflammatory processes contribute both to cell damage and tissue remodeling. The early release of alarmins triggers the upregulation of multiple proinflammatory cytokines, resulting in...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418818092

    authors: Dzyubenko E,Manrique-Castano D,Kleinschnitz C,Faissner A,Hermann DM

    更新日期:2018-12-17 00:00:00

  • Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study.

    abstract:Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with tra...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418802688

    authors: Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH

    更新日期:2018-09-28 00:00:00

  • Best practice in the use of natalizumab in multiple sclerosis.

    abstract::Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612470401

    authors: Fernández O

    更新日期:2013-03-01 00:00:00

  • New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

    abstract::More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common thera...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609355850

    authors: Chung SS

    更新日期:2010-03-01 00:00:00

  • Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.

    abstract:BACKGROUND:The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD:A retrospective 2-year chart review of all patie...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616661115

    authors: Rohracher A,Kalss G,Leitinger M,Granbichler C,Deak I,Dobesberger J,Kuchukhidze G,Thomschewski A,Höfler J,Trinka E

    更新日期:2016-11-01 00:00:00

  • Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome.

    abstract::Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286418793766

    authors: Araki M,Lin Y,Ono H,Sato W,Yamamura T

    更新日期:2018-08-18 00:00:00

  • Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

    abstract:Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420918088

    authors: Gklinos P,Mitsikostas DD

    更新日期:2020-04-28 00:00:00

  • Capsaicinoids in the treatment of neuropathic pain: a review.

    abstract::The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285613501576

    authors: Peppin JF,Pappagallo M

    更新日期:2014-01-01 00:00:00

  • Current and emerging therapies in multiple sclerosis: a systematic review.

    abstract::Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612450936

    authors: Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

    更新日期:2012-07-01 00:00:00

  • Diagnosis and management of essential tremor and dystonic tremor.

    abstract::Essential tremor (ET) is the most common adult movement disorder. Traditionally considered as a benign disease, it can cause an important physical and psychosocial disability. Drug treatment for ET remains poor and often unsatisfactory. Current therapeutic strategies for ET are reviewed according to the level of disco...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609104791

    authors: Gironell A,Kulisevsky J

    更新日期:2009-07-01 00:00:00

  • Natural toxins implicated in the development of Parkinson's disease.

    abstract::Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611413004

    authors: Salama M,Arias-Carrión O

    更新日期:2011-11-01 00:00:00

  • Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.

    abstract::Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420909973

    authors: Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

    更新日期:2020-06-03 00:00:00

  • Efficacy and safety of laquinimod in multiple sclerosis: current status.

    abstract::Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613499424

    authors: Haggiag S,Ruggieri S,Gasperini C

    更新日期:2013-11-01 00:00:00

  • Advances in imaging of brain abnormalities in neuromuscular disease.

    abstract::Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Schol...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286419845567

    authors: Angelini C,Pinzan E

    更新日期:2019-05-06 00:00:00

  • Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis.

    abstract:OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616650357

    authors: Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

    更新日期:2016-09-01 00:00:00

  • C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

    abstract:Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420935697

    authors: Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

    更新日期:2020-08-10 00:00:00

  • Vascular medicine and thrombectomy in stroke.

    abstract::The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285617742082

    authors: Fischer S,Weber W

    更新日期:2017-11-22 00:00:00

  • Botulinum toxin in the management of blepharospasm: current evidence and recent developments.

    abstract::Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285614557475

    authors: Hellman A,Torres-Russotto D

    更新日期:2015-03-01 00:00:00

  • Erythropoietin: still on the neuroprotection road.

    abstract::Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611434926

    authors: Subirós N,Del Barco DG,Coro-Antich RM

    更新日期:2012-05-01 00:00:00

  • Recent developments in MOG-IgG associated neurological disorders.

    abstract::In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meticulous clinical des...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420945135

    authors: Hegen H,Reindl M

    更新日期:2020-07-31 00:00:00

  • Can inflammation be resolved in Alzheimer's disease?

    abstract::Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418791107

    authors: Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

    更新日期:2018-08-09 00:00:00

  • Advances in spinal muscular atrophy therapeutics.

    abstract::Spinal muscular atrophy (SMA) is a progressive, recessively inherited neuromuscular disease, characterized by the degeneration of lower motor neurons in the spinal cord and brainstem, which leads to weakness and muscle atrophy. SMA currently represents the most common genetic cause of infant death. SMA is caused by th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285618754501

    authors: Parente V,Corti S

    更新日期:2018-02-05 00:00:00

  • Diagnosis and treatment of impulse control disorders in patients with movement disorders.

    abstract::Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613476127

    authors: Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

    更新日期:2013-05-01 00:00:00

  • Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.

    abstract:Background:No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective:To assess the NEDA status of...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418795085

    authors: Arnold DL,Shang S,Dong Q,Meergans M,Naylor ML

    更新日期:2018-08-28 00:00:00

  • Implementation of computer-based language therapy in aphasia.

    abstract::A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive computer-based language therapy program in a group of eight individuals with chronic...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609336548

    authors: Archibald LM,Orange JB,Jamieson DJ

    更新日期:2009-09-01 00:00:00